Vasopressin (AVP) plays a major role in the regulation of water and sodium homeostasis by its antidiuretic action on the kidney, mediated by V2 receptors. AVP secretion is stimulated by a rise in plasma osmolality, a decline in blood volume or stress. V1a receptors are expressed in vascular smooth muscle cells, but the role of vasopressin in blood pressure regulation is still a matter of debate. AVP may also play a role in some metabolic pathways, including gluconeogenesis, through its action on V1a receptors expressed in the liver. It is now understood that thirst and arginine vasopressin (AVP) release are regulated not only by the classical homeostatic, intero-sensory plasma osmolality negative feedback, but also by novel, extero-sensory, anticipatory signals. AVP measurement is time-consuming, and AVP level in the blood in the physiological range is often below the detection limit of the assays. Recently, an immunoassay has been developed for the measurement of copeptin, a fragment of the pre-provasopressin molecule that is easier to measure. It has been shown to be a good surrogate marker of AVP.
Introduction
The hormone vasopressin (AVP) or antidiuretic hormone (ADH) plays a major role in the control of body water homeostasis and associated disorders. Its possible role in blood pressure regulation remains controversial. Recently, its role in chronic renal, cardiovascular and metabolic diseases has been a matter of growing interest. This is mostly due to the availability of new tools. First, efficient orally active antagonists, the vaptans, offer the possibility of therapeutic interventions. Secondly, advances in the study of neurone biology have provided a new light in the mechanism of osmosensation and neuro-hormonal circuits leading to the release of the hormone. Thirdly, a recently developed immunoassay allows the measurement of copeptin, a surrogate of vasopressin that is more stable in vitro and much easier to measure than the hormone itself.
In this review, we will first provide a rapid survey of vasopressin physiology, receptors, target organs and multiple biological functions (beyond its role in the control of body fluid homeostasis) [1, 2] . Then, we will present the new advancements in the understanding of osmosensation and the neuronal pathways that lead to the secretion of the hormone. Finally, we will describe the measurement of copeptin and the wide opening this has provided in epidemiologic studies and as a diagnostic tool.
Overview of vasopressin physiology

Vasopressin synthesis and secretion
Vasopressin is a small peptidic hormone (MW = 1080) comprising nine amino acids in a ring structure. It is synthesized in the hypothalamus and stored in the neurohypophysis. The pre-prohormone protein contains vasopressin, neurophysin and copeptin that are cleaved in their course in the pituitary stalk and released simultaneously in the blood in equimolar amounts.
The primary function of vasopressin is to maintain body fluid balance by keeping plasma osmolality within narrow limits and allowing the kidneys to adapt water excretion to the body's needs, in conjunction with thirst. No other hormone can replace vasopressin: the lack of vasopressin results in diabetes insipidus (10-15 L urineÁday À1 ). Vasopressin has a very short biological half-life (about 3 min), and it is cleared mostly by filtration in the kidneys. Accordingly, its effects are very prompt and promptly reversible.
The plasma level of vasopressin in the usual range is very low (0 to 3 pgÁmL À1 % 3 9 10 À12 M), even the best assays are unable to quantify vasopressin in the low range of physiological values (the lowest threshold of most immuno assays is 0.5 pgÁmL
À1
). Vasopressin concentration in the urine is severalfold higher than that in the blood, but its excretion rate does not truly reflect its concentration in the blood because it is largely influenced by the osmolar excretion.
The main stimulus for the release of vasopressin is dehydration resulting in an increase in plasma osmolality. But for the same change in osmolality, sodium has a larger influence on vasopressin secretion than does urea or glucose [3] . Other stimuli for vasopressin secretion are a reduction in circulating blood volume and stress situations [4] . The threshold and slope for vasopressin secretion versus plasma osmolality is very reproducible in the same subjects and shows strong heritability [5] .
Vasopressin receptors and target site tissues
Three different receptors for vasopressin have been characterized [6] . The effects following V2 receptor (V2R) activation are mediated by cyclic AMP whilst the effects mediated by V1a or V1b (V1aR, and V1bR also called V3R) receptor activation are mediated by calcium signals. The commonly known target tissues for vasopressin are the kidney collecting duct (with V2R) and the vascular smooth muscle cells (with V1aR). But vasopressin receptors are expressed in a number of other organs and tissues (see Fig. 1 ) [7] . Moreover, V1aR are also expressed in the kidney, and V2R are expressed in the endothelium (where they play a vasodilatory role by inducing the formation of NO).
The sensitivity to vasopressin most probably differs amongst target organs, but this relative sensitivity is poorly documented. And this sensitivity may be modified by diverse physiological and pathologic adaptations. As an example, the stimulation of V1aR in the kidney requires higher concentration of vasopressin than the V2R effects [8] . Actually, the kidney V2R is exquisitely sensitive. In healthy humans, the infusion of vasopressin at rates of 1, 5 or 25 pgÁmin À1 per kg induced a significant, dosedependent antidiuretic action, but only the highest rate induced a measurable rise in plasma vasopressin [9] . dDAVP (de-amino 8D-arginine vasopressin) is a peptidic V2R-specific agonist, widely used in the diagnostic of disorders of water balance and in the treatment of central diabetes insipidus. Terlipressin (= glypressin), a (poorly) selective V1aR agonist, is used in hepatorenal syndrome and oesophageal varices. Recently, potent, nonpeptide, orally active, selective antagonists of V2R have been designed, such as tolvaptan [10] .
Vasopressin effects on the kidney V2 receptors are localized in the principal cells of the collecting duct (CD) and, to a lesser extent, in the thick ascending limb. Along the entire CD, vasopressin increases water permeability by promoting the insertion of aquaporin 2 (AQP2)-rich vesicles in the luminal membrane of the CD cells. This allows an increase in water reabsorption when a favourable osmotic driving force is present (generated by solute accumulation in the surrounding interstitium). In addition, vasopressin exerts two other effects on the CD through V2R (Fig. 2a) . (i) In the cortical and outer medullary CD, vasopressin stimulates sodium reabsorption by its action on the luminal sodium channel ENaC. This drives water iso-osmotically and thus helps concentrate all other solutes in the lumen. (ii). In the terminal inner medullary CD, vasopressin increases the permeability to urea by activating the facilitated urea transporters UT-A1 and UT-A3. This allows concentrated urea to diffuse in the medullary interstitium and thus maintain in the interstitium a high urea concentration that favours water reabsorption [11, 12] . In the thick ascending limb, vasopressin stimulates the Na-K-2Cl cotransporter NKCC2 and thus promotes sodium reabsorption. But this effect requires a higher concentration of the hormone than that on the CD [13] . Altogether, these combined effects on several membrane transporters and channels contribute jointly to urine concentration. These V2R-mediated effects are partially counteracted by V1aR effects in two ways. Luminal V1aR, exposed to urinary vasopressin, induces the production of prostaglandins by CD cells that, indirectly, attenuate the adenylate cyclase response to V2R stimulation. Secondly, V1aR are also abundantly expressed in interstitial cells of the medulla where they stimulate the production of prostaglandins that vasodilate the medullary vasculature. This opposes the possible vasoconstrictive effect of V1aR in the descending vasa recta and induces an increase in medullary blood flow that compromises the osmotic gradient of the medulla. Thus, there is a subtle balance between V2R and V1aR effects in the kidney, as demonstrated in rats [8, 11] .
Vasopressin action on the CD and thick ascending limb improve urine concentration, but they lead to some sodium and urea retention. The fractional excretion of sodium and urea (and most probably that of other solutes) is reduced when urine is more concentrated (Fig. 2b) . The vasopressin-dependent sodium retention may contribute to salt-sensitive hypertension and is compensated by the pressurenatriuresis mechanism [11] . The urea retention may lead to an increase in plasma urea concentration and, by an indirect mechanism, to a rise in glomerular filtration rate (GFR). It has been shown in both rats and humans that GFR increases with increasing urine osmolality (Fig. 3 ) [14] [15] [16] . This 'hyperfiltration' is probably an indirect consequence of the tubular action of vasopressin [17, 18] . In the long term, it may have adverse effects, as described elsewhere [17, 19] . An adverse effect of vasopressin is also observed in autosomal polycystic kidney disease, but through a different and more direct mechanism because AVP-dependent cAMP stimulates cyst enlargement (see ref. There are two different options for reducing vasopressin actions: either a voluntary increase in fluid intake [20] , or the use of selective vasopressin antagonists [10] . However, they differ in some aspects. An increase in water intake will lower plasma osmolality and vasopressin secretion. In contrast, V2R antagonists, that induce a water loss, will increase plasma osmolality and thus stimulate vasopressin secretion. The effects of vasopressin on V1a and V1b receptors may thus be potentiated. However, no rise in blood pressure has been observed in healthy subjects or patients treated with vaptans.
Effects on the liver and pancreatic islets
The expression of vasopressin V1aR in the liver and of V1bR in pancreatic islets was known for a long time, based mostly on in vitro studies in isolated perfused liver or pancreas or in isolated hepatocytes. But very little attention was given to the possible in vivo consequences of vasopressin action on these organs. It is now recognized that vasopressin stimulates the secretion of either insulin or glucagon by beta and alpha cells of the pancreas, respectively (depending on the level of glycemia). In the liver, vasopressin stimulates Glomerular filtration rate (GFR) was measured by inulin clearance in healthy subjects on two occasions at a two-week interval in random order: once with a high hydration (HH) and once with a low (normal) hydration (LH). In every subject, GFR was higher on the LH than on the HH condition (a). A significant correlation was observed between GFR and urine osmolality in the HH but not in the LH condition (b). Adapted from [15] . (c). In 74 normal rats with different levels of diuresis (during usual short term clearance experiments under anaesthesia), GFR is positively and linearly correlated with urine osmolality. Reproduced from [16] . (d) In normal rats in which urine concentration was either decreased or increased for one week (by increasing water intake or infusing dDAVP, respectively), GFR is positively and linearly correlated with urine osmolality. Adapted from [14] .
several metabolic pathways including glycogenolysis, gluconeogenesis and ureagenesis, glutamine and proline metabolism. These effects may differ according to fed or fasted condition and to glycemia. They are very similar to those induced by glucagon. But they occur through the activation of different second messengers (Ca ++ for AVP and cAMP for glucagon), suggesting that these effects might be additive.
In recent years, several studies have revealed significant associations between high vasopressin levels (or its diverse surrogates, low fluid intake, low urine flow rate, high osmolality or plasma copeptin concentration) and the prevalence or incidence of metabolic syndrome or diabetes (see other reviews in this journal). Interventional studies in humans and experimental studies in animal models are needed to further evaluate the contribution of vasopressin to renal and metabolic disorders. Figure 4 summarizes the multiple effects of vasopressin on the kidney and liver and their possible adverse consequences.
Recent advances in thirst perception and coordination of eating, drinking and vasopressin release
Mammals are 'osmoregulators'. They have evolved mechanisms that maintain extracellular fluid osmolality near a stable value [21] , yet values fluctuate around a set point : in humans, for example, 40 min of strenuous exercise [22, 23] It is now understood that thirst and argininevasopressin (AVP) release are regulated not only by the classical homeostatic, intero-sensory plasma osmolality negative feedback, but also by novel, extero-sensory, anticipatory signals.
Intero-sensory and extero-sensory regulation of thirst and vasopressin release
Deviations in intero-sensory stimuli Differences between the extracellular fluid (ECF) osmolality and the desired set point induce proportional homeostatic responses according to the principle of negative feedback [21, 27] (Fig. 5a) . ECF hyperosmolality stimulates the sensation of thirst [28] to promote water intake and the release of vasopressin [29] that will enhance water reabsorption in the kidney. By contrast, ECF hypoosmolality suppresses basal vasopressin secretion in rats and humans [30] . Thirst and vasopressin release appear thus far as a purely homeostatic response to deviations in intero-sensory stimuli: blood osmolality, pressure or volume. The techniques used in the 1960s and 1970s to describe these intero-sensory stimuli lacked the ability to track thirst neurones of the lamina terminalis and vasopressin neurones projecting to the posterior pituitary in real time in behaving animals and so could not assess extero-sensory information regulating these processes [31] .
Extero-sensory stimulation: anticipation for thirst stimulation and vasopressin release Recent experiments using optogenetic tools in awake animals demonstrate that a substantial fraction of normal drinking behaviour and vasopressin release is not regulated directly by changes in the blood and instead appears to anticipate homeostatic changes before they occur [32] . Anticipatory signals for thirst and vasopressin release converge on the same homeostatic neurones, subfornical organ neurones specifically, that monitor the tonicity of blood [28, 29] . Subfornical organ excitatory neurones (SFO Nos1 ) (Fig. 6 ) [33] [34] [35] [36] , activated by water restriction, had their activity rapidly returning to baseline after water access well before any measurable change in plasma osmolality occurs [28] . This rapid anticipatory response to drinking has been suggested by blood-oxygenlevel-dependent (BOLD signal) measurements during thirst stimulation in humans. The BOLD signal from the anterior cingulate cortex area, known to The ensuing depolarization increases the firing rate of action potential and vasopressin (VP) release from axon terminals in the neurohypophysis. Increased VP levels in blood enhance water reabsorption by the kidney (antidiuresis) to restore extracellular fluid osmolality towards the set point. Hypotonic stimuli inhibit TRPV1. The resulting hyperpolarization and inhibition of firing reduces VP release and promotes diuresis. Modified from [27] . (b) Shrinking of hypothalamic osmoreceptor neurones during dehydration is mechanically coupled to the activation of delta-N TRPV1 channels. As a result of cell shrinking, the plasma membrane shifts inward (right), increasing the proportion of microtubules that push onto (and activate) delta-N Trpv1 channels [36] . Reproduced with permission from [36] .
be responsible for the conscious perception of thirst, decreased rapidly after water consumption, well before any systemic absorption of water [37] . There is a delay of around ten minutes [21] between the ingestion of water and its full absorption into the bloodstream. These new data explain how drinking can quench thirst within seconds, long before the ingested water has had time to alter the blood volume or osmolality.
The rapid anticipatory response to drinking has at least two components: an immediate signal that tracks fluid ingestion and a delayed signal that reports on fluid tonicity, possibly generated by an oesophageal or gastric osmosensor. The alleviation of dry mouth information will flow up the fifth cranial trigeminal nerve, the taste of water will be relayed by the chorda tympani included into the seventh nerve, pharyngo-oesophageal impulses metering volume swallowed, by the ninth nerve and lower oesophageal and gastric sensationincluding distension -by the 10th cranial nerve, but the exact sensing receptors of these afferents are unknown. On a Darwinian point of view, the rapid, volumetrically exact intake of water consequent upon thirst or of a salt solution in case of sodium depletion carries high survival advantage: it permits animals to go to a water or salt source, to rapidly correct the deficit and leave the place, reducing their exposure to predators that have learned to wait there [38] .
Coordination of eating, drinking and vasopressin release Eating increases the need for water for two reasons: (i) there is a need to replace the fluid utilized . SFO neurones are activated when mice are dehydrated. This activity is almost immediately inhibited by drinking, owing to unknown signals that stem from the oral cavity, and which might act through the trigeminal ganglion. Other extero-sensory stimulation, implicating oesophageal or gastric osmosensor, is not represented. SFO neurones project to other median-pre-optic (MnPO) and organum vasculosum of the lamina terminalis (OVLT) circumventricular nuclei and to vasopressin producing neurones in the SFO and paraventricular nuclei (PVN) [33] . Dendritic release of vasopressin in the PVN is perceived by vasopressin V1a receptors on pre-autonomic neurones with consequent stimulation of renal afferents, a central control of volemia [34] : the lamina terminalis and autonomic nervous system are separated by just two synapses: excitatory neurones in the lamina terminalis project to neurones in the PVN which, in turn, send descending projections to autonomic regions of the hindbrain and spinal cord. PP, posterior pituitary; ANS, autonomic nervous system. Modified from [35] . for swallowing (saliva) and digestion (water diverted from the circulation into the gastrointestinal tract) and (ii) to counteract the increase in blood osmolality caused by the absorption of salts and other osmoles from food. As described recently in a review on thirst [32] , anticipatory signals about ongoing food ingestion are communicated to the lamina terminalis by multiple mechanisms. (i) Somatosensory signals from the oral cavity that report on food swallowing or its effects on the saliva. (ii) Several hormones associated with eating and satiety have been proposed to modulate thirst neurones and vasopressin release, including amylin, cholecystokinin, ghrelin, histamines, insulin and leptin. Some of these hormones might be increased in patients with diabetes mellitus and may explain their high vasopressin plasma concentration [39] . The responses to drinking and feeding are bidirectional, yet asymmetric : using electrophysiological recordings in genetically identified supraoptic nuclei pituitary-projecting vasopressin (VP pp ) neurones in water-restricted mice, Yael Mandelblat-Cerf et al. [29] observed rapid decreases in spiking within seconds of presentation of cues signalling water availability, beginning prior to water ingestion. In contrast, ingestion of dry food -a hyperosmotic challenge -elicited rapid increases in VP pp neurone activity, prior to any increase in plasma osmolality.
If prandial thirst is not quenched by drinking, then further food consumption is reduced, a phenomenon known as dehydration-induced anorexia that could be observed in young patients with congenital nephrogenic diabetes insipidus [40] .
Altogether, these new data explain the speed of thirst satiation, the fact that oral cooling is thirstquenching and the widespread coordination of eating, drinking and vasopressin release.
Osmosensitive cells shrinking during dehydration are mechanically coupled to the activation of delta-N TRPV1 channels All cells respond to dehydration or to hyperhydration by changing volume, but cells of the subfornical organ (SFO), organum vasculosum of the lamina terminalis (OVLT) and median preoptic nucleus (MnPO) of the hypothalamus are 'perfect' osmoreceptors; that is, their changes in volume are maintained as long as the osmotic stimulus persists [21, 27] . Cell shrinking during dehydration is mechanically coupled to the activation of delta-N TRPV1 channels [36] (a molecular codetector of body temperature and osmotic stress) through a densely interweaved microtubule network present only in osmosensitive cells (Fig. 5b) [27] , including excitatory thirst neurones from the SFO bearing angiotensin-I receptors. This coupling allows dehydration and decreased systemic volume stimuli to be integrated because SFO neurones are outside of the blood-brain barrier [33] . Systemic hypotonicity might be perceived by TRPV4 channels [41] .
Copeptin measurement as a surrogate marker for AVP release
With the development of immunoassay for several other pituitary hormones in the early 1970s, measurement of AVP became an obvious goal. The first AVP assay was developed by Robertson's group [42] . Like most other AVP assays [43] , it was a competitive radioimmunoassay (RIA). However, until today, AVP measurement remains cumbersome and complex. AVP can be measured only in a few specialized laboratories, and the data generated using existing assays have not convinced the clinical community to use AVP in their diagnostic workup studies.
Measurement of Copeptin as alternative to AVP
The discovery of the first prohormone by Donald Steiner in 1967 (see review in [44] ) and the successful use of the C-peptide of the insulin precursor as a surrogate marker for insulin release paved the way for a suitable alternative. The solution was to replace the problematic measurement of a bioactive, rapidly cleared peptide hormone-like AVP by the measurement of another larger peptide derived from its precursor and showing a better stability in vitro. Due to their stoichiometric generation, the amounts of prohormone fragments released reflect those of the respective mature hormones, offering an alternative way to assess the release of the hormone. Applying this approach to the AVP precursor, the C-terminal glycopeptide, termed 'copeptin' by Roger Acher [45] , is the ideal 'shadow' fragment reflecting AVP release (Fig. 7a) .
Several copeptin assays are now available. The only assays with sufficient technical description and clinical data justifying their routine clinical use are (i) the original sandwich immunoluminometric assay (LIA) as described previously [46] except that the capture antibody was replaced by a murine monoclonal antibody directed to amino acids 137-144 of pro-AVP and (ii) its automated immunofluorescent successor (on the KRYPTOR platform).
Both assays are CE certified and therefore approved for clinical use in the EU and some other countries accepting the CE mark. Other 'for research use only' assays are available in the USA and China, and individual 'home brew' assays are being developed by research groups. The disadvantage of these assays, besides not being approved or certified for patient care, lies in their lack of technical and clinical validation. As there is still no official reference calibration, it would seem reasonable to use only clinically approved and certified assays for patient care.
These are the advantages of copeptin measurement compared to AVP.
• Sample volume: The copeptin assay requires only 50 lL serum or plasma, whilst AVP assays need one or more mL of plasma.
• Extraction: No extraction step or other preanalytical procedures such as the addition of protease inhibitors is needed.
• Good ex vivo stability of copeptin in serum and plasma at room temperature [46] . than 48 h due to extensive incubation steps and the need for antibody equilibrium.
• Sensitivity: As a sandwich immunoassay, it is more sensitive than competitive AVP immunoassays, as demonstrated by the analytical detection limit of <1 pmol L
À1
. The assay can detect copeptin in plasma or serum even when plasma osmolality is low, whereas AVP is often not detectable in plasma samples within the low physiological range of osmolality. In healthy volunteers, plasma copeptin increased or decreased after infusion of hypotonic or hypertonic saline infusion, respectively. Here, copeptin followed the well-established pattern of AVP. Modified after [51] . (b) Plasma copeptin concentration and mean arterial pressure (MAP) in four baboons before, during and after haemorrhagic shock. The baboons were anesthetized and placed on a ventilator. They were then bled down to a MAP of 40 mmHg in two stages. During the first hour of resuscitation, the MAP was brought to 100 mmHg by the infusion of 25% of the shed blood plus Ringer solution, and during the third hour of resuscitation, an additional 25% of the shed blood plus Ringer solution was administered to raise the MAP to baseline levels. The total duration in hours and the time-points of blood draw during bleeding and reperfusion are indicated. R0 is the time-point after 3 h of bleeding and immediately before reperfusion was started. Reproduced from [53] .
• Stability: Copeptin, unlike AVP, is very stable ex vivo. Recovery was >80% in serum and plasma samples for at least 7 days at room temperature and 14 days at 4°C (Fig. 7b) .
Normal range of copeptin
The normal range for copeptin is now well defined. Copeptin and AVP levels have been compared in 500 subjects (equal numbers of each sex) of a French population [50] . A highly significant correlation was found between copeptin and AVP in the 319 people in whom both compounds were above the detection limit (r = 0.686, P < 0.001). The copeptin values were systematically higher than those for vasopressin and even more so in the low range of vasopressin [50] .
Influence of plasma or serum osmolality
In healthy subjects, copeptin (like mature AVP) is regulated within the normal range but may fluctuate according to physiological conditions. Copeptin increases towards higher values in the normal range during fasting and declines rapidly in vivo towards low normal values after intake of water [46] .
In a study of healthy volunteers, copeptin showed identical changes during disordered water states or osmolality as previously shown for AVP: water deprivation increased serum copeptin from 4.6 AE 1.7 to 9.2 AE 5.2 pmol L À1 (P < 0.0001). Copeptin increased from 4.9 AE 3.0 to 19.9 AE 4.8 pmol L À1 (P < 0.0001) with additional infusion of hypertonic saline. Conversely, copeptin decreased from 6.2 AE 2.4 to 2.4 AE 2.1 pmol L À1 (P < 0.01) during hypotonic saline infusion [51] (Fig. 8a) .
A direct comparison between copeptin and AVP serum concentrations in relationship to serum osmolality in healthy subjects was performed using the AVP assay established by Gary Robertson [52] . This comparison showed a stronger correlation between copeptin and serum osmolality (r = 0.77) than between AVP and serum osmolality (r = 0.49).
Influence of blood pressure
The effect of experimental haemorrhagic shock on copeptin was studied in a small number of baboons [53] . After induction of haemorrhagic shock, median copeptin increased sharply from 7.5 to 269 pmol L
À1
. Copeptin dropped after one hour of reperfusion and continued to decline until it reached a plateau of 24 pmol L À1 at the end of the experiment. The mean arterial blood pressure followed inverse kinetics in all animals, decreasing during bleeding and increasing slowly after reperfusion (Fig. 8b) [53] . This demonstrates that the response of copeptin to critical conditions like shock is much more pronounced than to changes in osmolality.
Influence of exercise
In healthy individuals, serum copeptin concentration in the blood increased during exercise, but did not exceed the 99th percentile of the normal range [46] . The situation is different in patients with cardiovascular disease. In patients with a history of angina pectoris undergoing a diagnostic treadmill exercise test, serum copeptin can increase to levels far beyond the normal range [54] .
Conclusion: copeptin for the clinician
The evidence to date shows that copeptin is a good surrogate marker for AVP release, and measuring copeptin is both practical and easy. Copeptin is now used in different clinical situations in which its measurement has helped in the diagnosis of disease or in management of the patients. This is reflected in the increasing number of copeptin publications since the development of the copeptin assay, and some of these studies are presented in this symposium issue of JIM.
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